KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Other Non Operating Income (2016 - 2025)

Emergent BioSolutions' Other Non Operating Income history spans 15 years, with the latest figure at -$13.8 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 9.21% year-over-year to -$13.8 million; the TTM value through Dec 2025 reached $48.5 million, up 7983.33%, while the annual FY2025 figure was $54.2 million, 8933.33% up from the prior year.
  • Other Non Operating Income reached -$13.8 million in Q4 2025 per EBS's latest filing, down from -$3.7 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $69.7 million in Q1 2025 to a low of -$15.2 million in Q4 2024.
  • Average Other Non Operating Income over 5 years is $1.8 million, with a median of -$2.6 million recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: plummeted 458.33% in 2022, then skyrocketed 2150.0% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$900000.0 in 2021, then skyrocketed by 844.44% to $6.7 million in 2022, then plummeted by 31.34% to $4.6 million in 2023, then tumbled by 430.43% to -$15.2 million in 2024, then grew by 9.21% to -$13.8 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Other Non Operating Income are -$13.8 million (Q4 2025), -$3.7 million (Q3 2025), and -$3.7 million (Q2 2025).